Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which lymphoma drug combo works best? a new study aims to find out

NCT ID NCT06170216

Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This study looks at how well different immunochemotherapy combinations, such as RCHOP, BR, and RCVP, work for people with small B-cell non-Hodgkin lymphoma. Researchers will track 206 adults with this type of lymphoma to see how many respond to treatment and how long they stay free of disease. The goal is to understand which treatment approaches are most effective and safest in real-world practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
immunochemotherapy combinations such as RCHOP, BR, and RCVP
What this could lead to
If this works, it could help doctors choose the most effective and safest immunochemotherapy for each patient with small B-cell lymphoma, improving outcomes and reducing side effects.
What could go wrong
This is an observational study, not a controlled experiment, so it cannot prove one treatment is better than another. Results may also be limited by the specific patient group at one center.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

206 people

The number who actually took part.

Started

Jan 2023

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligibale patients who ≥ 18 years old, Initial or first recurrent iNHL, with no contraindications to any medication in the treatment plan are enrolled. They will sign an informed consent form. Pregnant or lactating women were excluded. And patients who may not benefit from receiving immunochemotherapy evaluated by researchers are also excluded.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old * Initial or first recurrent iNHL confirmed by histopathology, including FL (1-3a), MZL, MCL; * Sign an informed consent form; * Researchers evaluate patients who can benefit from receiving immunochemotherapy. Exclusion Criteria: * There are contraindications to any medication in the treatment plan; * Pregnant or lactating women or male and female participants of childbearing age did not take contraceptive measures during the trial period and within 30 days after the last medication; * Researchers believe that patients who are not suitable for enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Follicular lymphoma grade 1-3A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma lymphoma, non-Hodgkin, familial mantle cell lymphoma marginal zone lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma, non-Hodgkin

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.